CNBC's Jim Cramer on Tuesday said it may be too soon to tell how GLP-1 diabetes and weight loss drugs will affect the stock of companies like Walmart or PepsiCo that sell food.
"Remember, it's one thing for interest rates to go higher and quash these stocks along with so many others.
It's another thing to put your stock portfolio at risk of an earnings miss, especially when the stock's more expensive than the rest of the market," Cramer said.
Cramer suggested PepsiCo's report could mean the drinks and snacks maker shouldn't fear the popularity of weight loss drugs, but he emphasized that it's too soon to tell either way.
Cramer also advised that investors take an interest in the bond market, locking in 10-year Treasurys while yields are high.
Persons:
CNBC's Jim Cramer, Cramer
Organizations:
Walmart, PepsiCo, Bloomberg, Wall